Company intelligence / Profile preview
Pliant Therapeutics
South San Francisco, California, United Statespliantrx.com ↗
- Ownership
- Public · PLRX
- Development stage
- Phase 2
01
Overview
Pliant recently discontinued its Phase 2b/3 BEACON-IPF trial of bexotegrast due to safety concerns, despite showing promising efficacy data regarding forced vital capacity (FVC). The company is now considering future dose-ranging Phase 2b studies with lower bexotegrast doses in pulmonary fibrosis and potentially other non-respiratory indications. The company announced a strategic realignment of its workforce on May 1, 2025, cutting 45% of staff.[7][9]
- Therapeutic areas
- GastroenterologyPulmonologyOncologyRare DiseasesNeurology
- Modalities
- Small moleculesmonoclonal antibodies
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Financials
- Market cap
- $50.5M
- Total revenue
- $0
- Enterprise value
- $-78.8M
Beyond the preview
Go deeper on Pliant Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pliant Therapeutics.